These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 21756818

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa.
    Maciá MD, Borrell N, Segura M, Gómez C, Pérez JL, Oliver A.
    Antimicrob Agents Chemother; 2006 Mar; 50(3):975-83. PubMed ID: 16495260
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa.
    Hansen GT, Zhao X, Drlica K, Blondeau JM.
    Int J Antimicrob Agents; 2006 Feb; 27(2):120-4. PubMed ID: 16426820
    [Abstract] [Full Text] [Related]

  • 5. A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa.
    Rhee MK, Kowalski RP, Romanowski EG, Mah FS, Ritterband DC, Gordon YJ.
    Am J Ophthalmol; 2004 Aug; 138(2):226-30. PubMed ID: 15289131
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effect of antibiotic sequence on combination regimens against Pseudomonas aeruginosa in a multiple-dose, in vitro infection model.
    Zelenitsky SA, Iacovides H, Harding GK, Ariano RE.
    Diagn Microbiol Infect Dis; 2004 May; 49(1):67-70. PubMed ID: 15135504
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
    Burkhardt O, Lehmann C, Madabushi R, Kumar V, Derendorf H, Welte T.
    J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
    [Abstract] [Full Text] [Related]

  • 14. Zymar (Gatifloxacin 0.3%) shows excellent Gram-negative activity against Serratia marcescens and Pseudomonas aeruginosa in a New Zealand White rabbit keratitis model.
    Mah FS, Romanowski EG, Kowalski RP, Yates KA, Gordon YJ.
    Cornea; 2007 Jun; 26(5):585-8. PubMed ID: 17525656
    [Abstract] [Full Text] [Related]

  • 15. Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion.
    Firsov AA, Smirnova MV, Strukova EN, Vostrov SN, Portnoy YA, Zinner SH.
    Int J Antimicrob Agents; 2008 Dec; 32(6):488-93. PubMed ID: 18790614
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. In vitro activities of the novel ceragenin CSA-13, alone or in combination with colistin, tobramycin, and ciprofloxacin, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients.
    Bozkurt-Guzel C, Savage PB, Gerceker AA.
    Chemotherapy; 2011 Dec; 57(6):505-10. PubMed ID: 22286090
    [Abstract] [Full Text] [Related]

  • 18. [Mutant prevention concentrations of fluoroquinolones for Staphylococcus aureus].
    Cui JC, Liu YN, Wang R, Liang BB, Pei F, Zheng ZJ.
    Zhonghua Yi Xue Za Zhi; 2004 Nov 17; 84(22):1863-6. PubMed ID: 15631794
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.